Cargando…

Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro

Sorafenib and regorafenib administration is among the preferential approaches to treat hepatocellular carcinoma (HCC), but does not provide satisfactory benefits. Intensive crosstalk occurring between cancer cells and other multiple non-cancerous cell subsets present in the surrounding microenvironm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dituri, Francesco, Scialpi, Rosanna, Schmidt, Tannin A., Frusciante, Martina, Mancarella, Serena, Lupo, Luigi Giovanni, Villa, Erica, Giannelli, Gianluigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669886/ https://www.ncbi.nlm.nih.gov/pubmed/33199679 http://dx.doi.org/10.1038/s41419-020-03180-8

Ejemplares similares

Proteoglycans in Cancer: Friends or Enemies? A Special Focus on Hepatocellular Carcinoma
por: Dituri, Francesco, et al.
Publicado: (2022)

Direct and Indirect Effect of TGFβ on Treg Transendothelial Recruitment in HCC Tissue Microenvironment
por: Dituri, Francesco, et al.
Publicado: (2021)

NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC
por: Cao, Yuan, et al.
Publicado: (2017)

Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression
por: Rani, Bhavna, et al.
Publicado: (2018)

Calcium Regulates HCC Proliferation as well as EGFR Recycling/Degradation and Could Be a New Therapeutic Target in HCC
por: Modica, Teresa Maria Elisa, et al.
Publicado: (2019)

Impaired Anti-Tumor T cell Response in Hepatocellular Carcinoma
por: Chaoul, Nada, et al.
Publicado: (2020)

Validation of a Lab-on-Chip Assay for Measuring Sorafenib Effectiveness on HCC Cell Proliferation
por: Piccinno, Emanuele, et al.
Publicado: (2021)

Validation of Hepatocellular Carcinoma Experimental Models for TGF-β Promoting Tumor Progression
por: Mancarella, Serena, et al.
Publicado: (2019)

Laminin-332 γ2 Monomeric Chain Promotes Adhesion and Migration of Hepatocellular Carcinoma Cells
por: Scialpi, Rosanna, et al.
Publicado: (2023)

The Interactivity between TGFβ and BMP Signaling in Organogenesis, Fibrosis, and Cancer
por: Dituri, Francesco, et al.
Publicado: (2019)

Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
por: D’Alessandro, Rosalba, et al.
Publicado: (2019)

TGF-β and the Tissue Microenvironment: Relevance in Fibrosis and Cancer
por: Caja, Laia, et al.
Publicado: (2018)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

The Tumor Microenvironment Drives Intrahepatic Cholangiocarcinoma Progression
por: Mancarella, Serena, et al.
Publicado: (2022)

Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020)

Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis
por: Mancarella, Serena, et al.
Publicado: (2020)

Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity
por: Yoshioka, Naoki, et al.
Publicado: (2019)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC
por: Trerotoli, Paolo, et al.
Publicado: (2009)

Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
por: De Matteis, Serena, et al.
Publicado: (2021)

Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC
por: Granito, Alessandro, et al.
Publicado: (2021)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
por: Guo, Lingling, et al.
Publicado: (2023)

Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models
por: Centonze, Matteo, et al.
Publicado: (2023)

Correction: Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models
por: Centonze, Matteo, et al.
Publicado: (2023)

Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
por: D’Alessandro, Rosalba, et al.
Publicado: (2014)

Upregulation of the oestrogen target gene SIX1 is associated with higher growth speed and decreased survival in HCV-positive women with hepatocellular carcinoma
por: Critelli, Rosina Maria, et al.
Publicado: (2022)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

GHR knockdown enhances the sensitivity of HCC cells to sorafenib
por: Gao, Shuang, et al.
Publicado: (2020)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
por: Brunetti, Oronzo, et al.
Publicado: (2019)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
por: Lee, Cheol-Hyung, et al.
Publicado: (2020)

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
por: Lee, I-Cheng, et al.
Publicado: (2022)

Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma
por: Zhang, Shun, et al.
Publicado: (2022)

Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
por: Bae, Heewon, et al.
Publicado: (2023)

Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib
por: Colombatto, Piero, et al.
Publicado: (2021)

Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report
por: Wan, Yanzhi, et al.
Publicado: (2023)

HCC Heterogeneity: Molecular Pathogenesis and Clinical Implications
por: Fransvea, Emilia, et al.
Publicado: (2009)

Correction: Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II
por: Dituri, Francesco, et al.
Publicado: (2013)

Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II
por: Dituri, Francesco, et al.
Publicado: (2013)

Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition
por: Mancarella, Serena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ps6ip0rrjk8p8k68c2fbmuhi1v